StockData
Genprex, Inc. logo

Genprex, Inc. (GNPX) shareholders

GNPXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.67−0.23 (-12.08%)

Close on Nov 17, 2026Market cap $1.37MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
1.7%
0M of 1M shares
Institutional holders
28
7 new, 5 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $22

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GNPXValueChange% of portfolio
Vanguard Fiduciary Trust Co3,5500.43%$40.54KNew0.00%
Hrt Financial LP3,2760.40%$37.00KNew0.00%
Geode Capital Management, LLC2,7430.33%$31.32K+1,2260.00%
Vanguard Capital Management LLC1,6520.20%$18.87K+1,3820.00%
Engineers Gate Manager LP9490.12%$10.84KNew0.00%
Mayflower Financial Advisors, LLC9090.11%$10.38K–0.00%
UBS Group AG2040.02%$2.33K+2040.00%
Tower Research Capital LLC (TRC)1290.02%$1.48KNew0.00%
Barclays PLC720.01%$819New0.00%
Jones Financial Companies Lllp550.01%$597−410.00%
Cheviot Value Management, LLC450.01%$519–0.00%
BlackRock, Inc.90.00%$98–0.00%
Harbour Investments, Inc.50.00%$56–0.00%
Osaic Holdings, Inc.40.00%$41−70.00%
SBI Securities Co., Ltd.20.00%$25–0.00%
Bernard Wealth Management Corp.10.00%$16−80.00%
Integrated Wealth Concepts LLC10.00%$11New0.00%
Allworth Financial LP10.00%$12+10.00%
Caitong International Asset Management Co., Ltd00.00%$1–0.00%
Capital Advisors, Ltd. LLC00.00%$0–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026280M1.7%7 / 43 / 50M0M
Q1 2026270M0.5%11 / 21 / 40M0M
Q4 2025220M0.0%21 / 00 / 00M0M
Q3 202510M0.0%1 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Ryan M. ConferPresident, CEO and CFO, Director36,3314.43%Feb 27, 2026
Mark Stanley BergerChief Medical Officer21,6922.65%Feb 27, 2026
Brent M. LongneckerDirector9,1571.12%Apr 15, 2026
William R. Wilson Jr.Director9,1571.12%Dec 23, 2025
Toscano Jose Antonio MorenoDirector9,1571.12%Dec 23, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Brent M. Longnecker
Director
Apr 14, 2026Sale−10$1.23$120
Brent M. Longnecker
Director
Apr 14, 2026Sale−8$1.23$109,157
Mark Stanley Berger
Chief Medical Officer
Feb 27, 2026Tax withholding−7,168$2.00$14.34K21,692
Ryan M. Confer
President, CEO and CFO, Director
Feb 27, 2026Tax withholding−9,330$2.00$18.66K36,331
Toscano Jose Antonio Moreno
Director
Dec 22, 2025Award+9,000––9,157
Brent M. Longnecker
Director
Dec 22, 2025Award+9,000––9,165
Ryan M. Confer
President, CEO and CFO, Director
Dec 22, 2025Award+45,000––45,661
Mark Stanley Berger
Chief Medical Officer
Dec 22, 2025Award+28,500––28,860
William R. Wilson Jr.
Director
Dec 22, 2025Award+9,000––9,157
Ryan M. Confer
President, CEO and CFO, Director
Jun 30, 2025Tax withholding−5,775$0.23$1.33K32,968
Mark Stanley Berger
Chief Medical Officer
Jun 30, 2025Tax withholding−4,500$0.23$1.04K17,971
Mark Stanley Berger
Chief Medical Officer
Feb 18, 2025Tax withholding−585$0.41$24022,471
Ryan M. Confer
President, CEO and CFO, Director
Feb 18, 2025Tax withholding−395$0.41$16238,743
Ryan M. Confer
President, CEO and CFO, Director
Dec 5, 2024Award+29,375––39,138
William R. Wilson Jr.
Director
Dec 5, 2024Award+4,750––7,845
Brent M. Longnecker
Director
Dec 5, 2024Award+4,750––8,220
Mark Stanley Berger
Chief Medical Officer
Dec 5, 2024Award+18,250––23,056
Toscano Jose Antonio Moreno
Director
Dec 5, 2024Award+4,750––7,845
Ryan M. Confer
Chief Financial Officer
Feb 18, 2024Tax withholding−1,126$4.40$4.95K9,763
Mark Stanley Berger
Chief Medical Officer
Feb 18, 2024Tax withholding−1,319$4.40$5.80K4,806
John Rodney Varner
Chairman, President and CEO, Director
Feb 18, 2024Tax withholding−2,642$4.40$11.62K26,352
William R. Wilson Jr.
Director
Jun 27, 2023Award+123,795––123,795
Toscano Jose Antonio Moreno
Director
Jun 27, 2023Award+123,795––123,795
Brent M. Longnecker
Director
Jun 27, 2023Award+123,795––138,795
John Rodney Varner
Chairman, President and CEO, Director
Apr 21, 2023Buy+19,000$1.06$20.14K20,800
Catherine M. Vaczy
EVP GC Chief Strategy Officer
Apr 21, 2023Buy+20,000$1.07$21.40K265,000
Mark Stanley Berger
Chief Medical Officer
Feb 18, 2023Award+245,000––245,000
Hermant Kumar
Chief Mfgr & Tech Officer
Feb 18, 2023Award+200,000––200,000
John Rodney Varner
President & CEO, Director
Feb 18, 2023Award+625,000––1,159,735
Ryan M. Confer
Chief Financial Officer
Feb 18, 2023Award+245,000––435,499
Catherine M. Vaczy
EVP GC Chief Strategy Officer
Feb 18, 2023Award+245,000––245,000
Ryan M. Confer
Chief Financial Officer
Jul 28, 2022Option exercise+116,973$0.02$2.34K190,499
John Rodney Varner
President & CEO, Director
Jun 14, 2021Gift−1,614,152––0
Brent M. Longnecker
Director
Apr 5, 2021Buy+15,000$4.15$62.25K15,000
John Rodney Varner
Chief Executive Officer, Director, 10% owner
Sep 5, 2019Buy+1,800$0.89$1.60K1,800
Jack A. Roth
10% owner
Dec 5, 2018Other−250,000––814,853
Jack A. Roth
10% owner
Dec 5, 2018Other−0––646,960
Viet-An Hoan Ly
10% owner
Sep 27, 2018Other−583,008––0
Viet-An Hoan Ly
10% owner
Sep 27, 2018Other−102,000––0
Viet-An Hoan Ly
10% owner
Sep 27, 2018Other−475,974––36,067
Julien L. Pham
President & COO
Jul 30, 2018Buy+500$3.40$1.70K500
Jack A. Roth
10% owner
Mar 29, 2018Buy+40,000$5.00$200.00K1,338,999
John Rodney Varner
Chief Executive Officer, Director, 10% owner
Mar 29, 2018Buy+10,000$5.00$50.00K544,735
Christy M. Nance
10% owner
Mar 29, 2018Buy+50,000$5.00$250.00K50,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
16.79%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-1.3%
From 0M shares
Short volume, 20 days
33.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Genprex's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,660 shares on Sep 24, 2026 over the last 90 days.

Congress trades

4 trades in Genprex reported by 1 member of the House

MemberTypeTradedAmountFiled
Tim Moore
NC14
BoughtFeb 5, 2026$1K–15KFeb 20, 2026
Tim Moore
NC14
BoughtDec 18, 2025$1K–15KJan 7, 2026
Tim Moore
NC14
BoughtNov 7, 2025$1K–15KDec 2, 2025
Tim Moore
NC14
BoughtOct 29, 2025$15K–50KNov 12, 2025

See a number that looks wrong?